{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:03:18Z","timestamp":1782889398391,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1746,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/modpathol.2017.174","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:40:36Z","timestamp":1515742836000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1\/2-related, but not MYC- or p-STAT3-related cell signaling"],"prefix":"10.1016","volume":"31","author":[{"given":"Xuejun","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Dorfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2017.174_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of polycomb gene silencing: knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/modpathol.2017.174_bib2","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.18632\/oncotarget.6612","article-title":"Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.174_bib3","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in normal hematopoiesis and hematological malignancies","volume":"7","author":"Herviou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.174_bib4","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","article-title":"Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and p-STAT3 expression in a subset of cases","volume":"56","author":"Shi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2017.174_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","article-title":"Differential expression of Enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas","volume":"29","author":"Tian","year":"2016","journal-title":"Mod Pathol"},{"issue":"Suppl 6","key":"10.1038\/modpathol.2017.174_bib6","doi-asserted-by":"crossref","first-page":"S1057","DOI":"10.21037\/tcr.2016.11.18","article-title":"New insights into the mechanisms of EZH2's promotion of oncogenesis","volume":"5","author":"Dorfman","year":"2016","journal-title":"Transl Cancer Res"},{"key":"10.1038\/modpathol.2017.174_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.174_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2017.174_bib9","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","article-title":"A687V EZH2 is a gain-of-function mutation found in lymphoma patients","volume":"586","author":"Majer","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1038\/modpathol.2017.174_bib10","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.174_bib11","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Poc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.174_bib12","first-page":"1329","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B-cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Cell Chem Biol"},{"key":"10.1038\/modpathol.2017.174_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.174_bib14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.174_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.174_bib16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib17","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.174_bib18","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"10.1038\/modpathol.2017.174_bib20","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib22","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/MCB.00162-07","article-title":"Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells","volume":"27","author":"Shi","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1038\/modpathol.2017.174_bib23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF- \u03baB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol Cell"},{"key":"10.1038\/modpathol.2017.174_bib24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib25","doi-asserted-by":"crossref","first-page":"78355","DOI":"10.18632\/oncotarget.13058","article-title":"High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasm","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.174_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5430\/crcp.v3n4p45","article-title":"A rare case of follicular lymphoma with transformation to diffuse large B-cell lymphoma and trans-differentiation to histiocytic sarcoma","volume":"3","author":"Rjoop","year":"2016","journal-title":"Case Reports Clin Pathol"},{"key":"10.1038\/modpathol.2017.174_bib27","doi-asserted-by":"crossref","first-page":"17324","DOI":"10.1074\/jbc.M800224200","article-title":"Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation","volume":"283","author":"Fujii","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1038\/modpathol.2017.174_bib28","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/onc.2011.118","article-title":"MEK\u2013ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes","volume":"30","author":"Fujii","year":"2011","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2017.174_bib29","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans' cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3109\/10428194.2014.946028","article-title":"BRAF V600E mutation-specific immunohistochemistry is a rare finding and dendritic cell- and histiocytic-derived tumors","volume":"56","author":"Fedoriw","year":"2014","journal-title":"Leuk Lymph"},{"key":"10.1038\/modpathol.2017.174_bib31","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.18632\/oncotarget.2061","article-title":"Potential clinical implications of BRAF mutations in histiocytic proliferations","volume":"5","author":"Bubolz","year":"2014","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.174_bib32","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated histiocytoses biomarkers beyond BRAFV600 E: frequent expression of PD-L1","volume":"6","author":"Gatalica","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.174_bib33","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","article-title":"Frequent detection of BRAF V600 E mutations in histiocytic and dendritic cell neoplasms","volume":"65","author":"Go","year":"2014","journal-title":"Histopathology"},{"key":"10.1038\/modpathol.2017.174_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00428-016-1965-2","article-title":"Somatic mutations in histiocytic sarcoma identified next generation sequencing","volume":"469","author":"Liu","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1038\/modpathol.2017.174_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13256-017-1253-z","article-title":"BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report","volume":"11","author":"Vaughn","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1038\/modpathol.2017.174_bib37","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1212\/WNL.0000000000000880","article-title":"Dramatic response of a BRAF V600E\u2013mutated primary CNS histiocytic sarcoma to vemurafenib","volume":"83","author":"Idbaih","year":"2014","journal-title":"Neurology"},{"key":"10.1038\/modpathol.2017.174_bib38","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1080\/15384047.2015.1057359","article-title":"The Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature","volume":"16","author":"Di Liso","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/modpathol.2017.174_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.anndiagpath.2015.02.008","article-title":"Evidence of BRAF V600 E in indeterminant cell tumor and interdigitating dendritic cell sarcoma","volume":"19","author":"O'Malley","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"10.1038\/modpathol.2017.174_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","article-title":"High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans' cell histiocytosis","volume":"124","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib41","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.174_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1593\/neo.07971","article-title":"Inhibition of JAK1, 2\/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells","volume":"10","author":"Xiong","year":"2008","journal-title":"Neoplasia"},{"key":"10.1038\/modpathol.2017.174_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/path.4179","article-title":"Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer","volume":"230","author":"Lin","year":"2013","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2017.174_bib44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2017.174_bib45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.174_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/nyas.12356","article-title":"Targeting epigenetic regulators for cancer therapy","volume":"1309","author":"Wee","year":"2014","journal-title":"Ann NY Acad Sci"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222007566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/modpathol.2017.174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2017174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:38:57Z","timestamp":1760229537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222007566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0893395222007566"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2017.174","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1\/2-related, but not MYC- or p-STAT3-related cell signaling","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2017.174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}